Comparison · NCT00322452-10088bbd
Gefitinib vs Carboplatin/Paclitaxel: Objective Tumour Response Rate According to RECIST
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Gefitinib vs Carboplatin/Paclitaxel: Objective Tumour Response Rate According to RECIST. Trial comparisons, record NCT00322452-10088bbd. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00322452-10088bbd
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.43 | 0.391 | 0.47 | wilson | |
| Risk in group 2 | 0.322 | 0.286 | 0.361 | wilson | |
| Risk difference, group 1 minus group 2 | 0.108 | 0.0534 | 0.161 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.33 | 1.15 | 1.55 | log | |
| Odds ratio, group 1 over group 2 | 1.59 | 1.26 | 2.01 | log | |
| Number needed to treat, for one more participant with the outcome on Gefitinib than on Carboplatin/Paclitaxel | 9.27 | 6.2 | 18.7 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Gefitinib | Gefitinib 250mg daily | 262 | 609 | OG000 |
| Group 2 | Carboplatin/Paclitaxel | Carboplatin AUC 5.0 or 6.0 and Paclitaxel 200 mg/m\^2 doublet chemotherapy every 3 weeks | 196 | 608 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Objective Tumour Response Rate According to RECIST
- Description
Number of participants with an objective response. An objective response (OR) was defined as a patient having a best overall response of either complete response (CR) or partial response (PR) according to RECIST, confirmed at least 28 days following the date of the initial response.
- Time frame
- Tumour assessments as per RECIST were performed at baseline and then every 42 days ± 7 days from randomization until data cut off (14th April 2008).
- Population
- Analysis was carried out on Intention-to-treat (ITT) population.
Source ClinicalTrials.gov
Trial
- Title
- First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia
- NCT number
- NCT00322452
- Phases
- PHASE3
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Gefitinib, Carboplatin, Paclitaxel
- Lead sponsor
- AstraZeneca
- Results first posted
- 2010-05-17
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00322452?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00322452-10088bbd